HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

Poloxamer (Poloxamer 407)

A nonionic polyoxyethylene-polyoxypropylene block co-polymer with the general formula HO(C2H4O)a(-C3H6O)b(C2H4O)aH. It is available in different grades which vary from liquids to solids. It is used as an emulsifying agent, solubilizing agent, surfactant, and wetting agent for antibiotics. Poloxamer is also used in ointment and suppository bases and as a tablet binder or coater. (Martindale The Extra Pharmacopoeia, 31st ed)

Also Known As:

Poloxamer 407; Poloxamers; Pluronic F-108; Pluronic F-127; Pluronic F-68; Pluronic F68; Pluronic L-101; Pluronic L-121; Pluronic L-81; Pluronics; Poloxalkol; Poloxamer 188; Poloxamer 213; Poloxamer 2930; Poloxamer 338; Pluronic F 108; Pluronic F 127; Pluronic F 68; Pluronic F108; Pluronic F127; Pluronic L 101; Pluronic L 121; Pluronic L 81; Pluronic L101; Pluronic L121; Pluronic L81; alpha-Hydro-omega-hydroxypoly(oxyethylene)a-poly(oxopropylene)b-poly(oxyethylene)a block copolymer

Networked: 376 relevant articles (33 outcomes, 60 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Johnston, Thomas P: 11 articles (03/2013 - 06/2003)
2.	Cho, Chong-Su: 6 articles (01/2013 - 02/2006)
3.	Song, Cunxian: 6 articles (06/2010 - 01/2009)
4.	Mei, Lin: 5 articles (06/2010 - 01/2009)
5.	Sun, Hongfan: 5 articles (06/2010 - 01/2009)
6.	Choi, Han-Gon: 4 articles (12/2015 - 08/2005)
7.	Korolenko, T A: 4 articles (11/2015 - 06/2013)
8.	Oh, Se Heang: 4 articles (01/2014 - 03/2005)
9.	Lee, Jin Ho: 4 articles (01/2014 - 03/2005)
10.	Brocks, Dion R: 4 articles (01/2013 - 01/2006)

Related Diseases

1.	Wounds and Injuries (Trauma) 08/01/2008 - "Poloxamer 188 (P188), a nonionic block copolymer chemical surfactant known to have cytoprotective, rheologic, anti-inflammatory, and anti-thrombotic activity, has shown promise in the management of selected trauma patients. " 08/16/2007 - "The wound healing efficacy of CS/poloxamer SIPNs as a wound dressing was evaluated on experimental full thickness wounds in a mouse model. " 05/01/2012 - "In this study, intradermal treatment of excisional wounds of stressed mice with 2mg/ml KSLW loaded in Pluronic F68, resulted in a sustained antimicrobial effect through post-operative day 5, with a 2-log (p<0.01) reduction in bacterial load compared with other stressed mice. " 10/01/2015 - "The gel-treated and SA-treated wounds received topically 400 μl of pluronic F-127 gel (25%) and 400 μl of SA (0.3%) in pluronic gel, respectively, once daily for 19 days. " 12/01/2014 - "Therefore, our results suggest that NaB, and its pluronics combination, could be used in dermatological clinics and be a future solution for chronic wounds. "
2.	Neoplasms (Cancer) 01/01/2015 - "A functional drug delivery platform for targeting and imaging cancer cells based on Pluronic F127." 05/01/2012 - "Viral injection in SELP 815K produced a greater level and more prolonged extent of gene expression in the tumor, a statistically greater tumor size reduction, a longer time until tumor rebound, and a significantly increased survivability, as compared to injection of virus alone or in Poloxamer 407. " 02/01/2012 - "The LMw MC gel/Pluronic F127 micelle combination system constitutes a promising tool for reducing tumor size and eradicating remaining tumor cells before and after surgery." 04/01/2011 - "Poly(diethylaminoethylmethacrylate) (PDEAEM) and Pluronic F127 based pentablock copolymer vectors with the ability to transfect cancer cells selectively over normal cells in in vitro cultures were developed, as described in a previous report. " 04/01/2011 - "Previous work demonstrated that the poly(diethylaminoethylmethacrylate) (PDEAEM)/Pluronic F127 pentablock copolymers exhibit transfection in vitro selectively in cancer cell lines as opposed to non-cancerous cell lines. "
3.	Myocardial Infarction 08/01/1996 - "Poloxamer 188-treated patients demonstrated a 38% reduction in median myocardial infarct size (25th and 75th percentile) compared with placebo (16% [7, 30] versus 26% [9, 43]; P = .031), greater median myocardial salvage (13% [7, 20] versus 4% [1, 15]; P = .033), and a 13% relative improvement in median ejection fraction (52% [43, 60] versus 46% [35, 60]; P = .020). " 12/01/1994 - "A 48-hour infusion of poloxamer 188 reduced myocardial infarct size and improved left ventricular function in this dog model of 90 minutes of coronary artery occlusion and 72 hours of reperfusion. " 08/01/2000 - "Mortality and reinfarction rate were measured in 2770 patients with acute myocardial infarction who received thrombolysis within 12 hours in CORE, an international, dose ranging trial of poloxamer 188. " 04/01/1998 - "RheothRx injection is an intravenous formulation of Poloxamer 188, a non-ionic block copolymer surfactant which is actually used in clinical studies, e.g., during thrombolysis in acute myocardial infarction. " 07/01/1997 - "Previous studies suggested that RheothRx (poloxamer 188) reduces infarct size and improves left ventricular (LV) function in acute myocardial infarction (AMI). "
4.	Reperfusion Injury 02/01/2015 - "Poloxamer 188 (P188) has also proven beneficial to neuronal and cardiac tissue during reperfusion injury in human and animal models. " 01/01/2013 - "Poloxamer 188 protects neurons against ischemia/reperfusion injury through preserving integrity of cell membranes and blood brain barrier." 06/01/2010 - "The authors postulated that a single-dose administration of poloxamer 188 would decrease skeletal myocyte injury and mortality following ischemia-reperfusion injury. " 06/01/2010 - "Poloxamer 188 protects against ischemia-reperfusion injury in a murine hind-limb model." 01/01/2010 - "Poloxamer 188 inhibition of ischemia/reperfusion injury: evidence for a novel anti-adhesive mechanism."
5.	Hemorrhage 11/01/2011 - "The surfactant poloxamer 188 (P188) has been shown to improve survival following hemorrhage. " 07/01/1994 - "It is postulated that poloxamer 188 would improve outcome if administered during retransfusion following hemorrhage. " 03/01/2010 - ": To check the efficacy of a reverse thermosensitive gel (poloxamer P407) for intracoronary shunt sealing in off-pump coronary artery bypass surgery to stop residual bleeding from the shunt and avoid the use of blowers. " 11/01/2011 - "Severe controlled hemorrhage resuscitation with small volume poloxamer 188 in sedated miniature swine." 01/01/2007 - ": To evaluate a new material, poloxamer 407 reverse-thermal polymer, which may be of value in controlling bleeding during off-pump coronary anastomoses. "

Related Drugs and Biologics

1.	Poloxamer (Poloxamer 407)
2.	UCON 50-HB-5100 (F127)
3.	Ibuprofen (Motrin)
4.	alginic acid (sodium alginate)
5.	Micelles
6.	Polymers
7.	Paclitaxel (Taxol)
8.	Polysorbates (PSML)
9.	polycaprolactone
10.	Sodium

Related Therapies and Procedures

1.	Injections
2.	Drug Therapy (Chemotherapy)
3.	Angioplasty (Angioplasty, Transluminal)
4.	Electrodes (Electrode)
5.	Thrombolytic Therapy